Poster-Disease-modifying Therapy
October 25, 2021
Agnos Study Design: A Phase 4 Study Assessing Ofatumumab in Treatment-Naïve Young Adults with Early Relapsing Remitting MS Benchmarked Against Healthy Controls
Background: Early intervention with high efficacy therapies has been shown to reduce long-term disability accrual in patients with multiple...
Poster-Disease-modifying Therapy
October 25, 2021
Efficacy of Ofatumumab on Microglial Activity in Patients with Relapsing Forms of Multiple Sclerosis: Interim Analysis
INTRODUCTION Ofatumumab, a fully-human anti-CD20 monoclonal antibody, is indicated for the treatment of relapsing forms of multiple...
Poster-Disease-modifying Therapy
October 25, 2021
Long-Term Effect of Siponimod on MRI Outcomes in Secondary Progressive Multiple Sclerosis: Analyses from the Expand Study up to 5 Years
Background: In the Phase 3 EXPAND core study, siponimod compared with placebo significantly reduced disability progression, cognitive...
Poster-Disease-modifying Therapy
October 25, 2021
Comparison of Therapy Selection Drivers within the S1P Receptor Modulator and Fumarate Classes Among Multiple Sclerosis Patients Who Recently Switched Treatment
Background: The number of disease-modifying therapies (DMTs) within the S1P receptor modulator and fumarate classes has expanded with...
Poster-Disease-modifying Therapy
October 25, 2021
Safety of Eculizumab in Nmosd and MG Analysis of the Phase 3 Studies Prevent and Regain and Their Extensions
Background: Aquaporin-4 immunoglobulin G-positive neuromyelitis optica spectrum disorder (AQP4+ NMOSD) and acetylcholine receptor...
Poster-Disease-modifying Therapy
October 25, 2021
Safety and Efficacy of Siponimod in Patients with Active Secondary Progressive Multiple Sclerosis Identifying As Hispanic from the Expand Study
Background: In the Phase 3 EXPAND trial siponimod, a selective S1P receptor modulator, significantly reduced risk of 3-month and 6-month...
Poster-Disease-modifying Therapy
October 25, 2021
Safety of Evobrutinib in Patients with Relapsing Multiple Sclerosis Is Maintained in a Long-Term Open-Label Extension of a Phase II Study
Background: In a 48-week Phase II study NCT02975349, in patients with relapsing multiple sclerosis, evobrutinib was generally...
Poster-Disease-modifying Therapy
October 25, 2021
The Benefits of Azathioprine in Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease: A Systematic Review and Meta-Analysis
Background: MOGAD is an emerging inflammatory demyelination disorder of the central nervous system. AZA is one of the commonly used...
Poster-Disease-modifying Therapy
October 25, 2021
A Single Center Retrospective Analysis of Insurance Policy Impact on the Choice of Multiple Sclerosis Disease Modifying Therapies
Background: Financial barriers to disease modifying therapies (DMT) for multiple sclerosis (MS) have been widely reported; yet the impact...
Poster-Disease-modifying Therapy
October 25, 2021
Therapy Selection Considerations during the COVID-19 Pandemic Among Patients with Progressive Multiple Sclerosis: Analyses from Retrospective Patient Chart Audit
Background: In March 2020, the onset of the COVID-19 pandemic in the United States introduced new concerns related to the treatment of...